Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Enrolling by invitationOBSERVATIONAL
Enrollment

225

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

November 30, 2027

Conditions
Traumatic Intracranial Hemorrhage
Interventions
DIAGNOSTIC_TEST

Repeat Thromboelastography with Platelet Mapping

Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.

Trial Locations (1)

17602

Penn Medicine Lancaster General Health, Lancaster

All Listed Sponsors
lead

Lancaster General Hospital

OTHER